Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain

Journal of Immunological Methods

Volumn 349, Issue 1-2, 2009, Pages 45-55

  Irwan, Yetty Y ^a,b   Feng, Yi ^a   Gach, H Michael ^a   Symanowski, James T ^a   McGregor, John R ^a   Veni, Gopalkrishna ^a   Schabel, Matthias ^b   Samlowski, Wolfram E ^a  

^a NEVADA CANCER INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain edema; Cytokines; DCE MRI; Interleukin 2; Mouse model; Neuropsychiatric toxicity

Indexed keywords

FLUORESCEIN SODIUM; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VESSEL; BRAIN EDEMA; BRAIN MICROCIRCULATION; BRAIN WATER; BRAIN WEIGHT; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY ANALYSIS; VASODILATATION;

ANIMALS; BRAIN; CAPILLARY PERMEABILITY; FEMALE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C3H; ORGAN SIZE; SPECIFIC PATHOGEN-FREE ORGANISMS; VASCULAR DISEASES;

MUS;

EID: 70149115865     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.07.014     Document Type: Article

References (54)

1. Alexander J.T., Saris S.C., and Oldfield E.H. The effect of interleukin-2 on the blood-brain barrier in the 9 L gliosarcoma rat model. J. Neurosurg. 70 (1989) 92
2. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., and Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17 (1999) 2105
3. Atkins M.B., Kunkel L., Sznol M., and Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 Suppl 1 (2000) S11
4. Brenner B.M., Troy J.L., and Ballermann B.J. Endothelium-dependent vascular responses. Mediators and mechanisms. J. Clin. Invest. 84 (1989) 1373
5. Dafni H., Kim S.J., Bankson J.A., Sankaranarayanapillai M., and Ronen S.M. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn. Reson. Med. 60 (2008) 822
6. Daldrup H., Shames D.M., Wendland M., Okuhata Y., Link T.M., Rosenau W., Lu Y., and Brasch R.C. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am. J. Roentgenol. 171 (1998) 941
7. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., Chang A.E., Rosenstein D., and Rosenberg S.A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107 (1987) 293
8. Dorr A., Sled J.G., and Kabani N. Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. Neuroimage 35 (2007) 1409
9. Eberlein T.J., Rosenstein M., and Rosenberg S.A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156 (1982) 385
10. Ellison M.D., Povlishock J.T., and Merchant R.E. Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res. 47 (1987) 5765
11. Ettinghausen S.E., Puri R.K., and Rosenberg S.A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst. 80 (1988) 177
12. Feng Y., Jeong E.K., Mohs A.M., Emerson L., and Lu Z.R. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn. Reson. Med. 60 (2008) 1347
13. Gemlo B.T., Palladino Jr. M.A., Jaffe H.S., Espevik T.P., and Rayner A.A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 48 (1988) 5864
14. Hank J.A., Kohler P.C., Weil-Hillman G., Rosenthal N., Moore K.H., Storer B., Minkoff D., Bradshaw J., Bechhofer R., and Sondel P.M. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res. 48 (1988) 1965
15. Harker W.G., Tom C., McGregor J.R., Slade L., and Samlowski W.E. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Cancer Res. 50 (1990) 5931
16. Hawkins B.T., and Egleton R.D. Fluorescence imaging of blood-brain barrier disruption. J. Neurosci. Methods 151 (2006) 262
17. Hornyak S.C., Orentas D.M., Karavodin L.M., and Gehlsen K.R. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice. Vascul. Pharmacol. 42 (2005) 187
18. Jablons D.M., Mule J.J., McIntosh J.K., Sehgal P.B., May L.T., Huang C.M., Rosenberg S.A., and Lotze M.T. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J. Immunol. 142 (1989) 1542
19. Kawamura S., and Yasui N. In vivo effects of the Ca2+ entry blocker nilvadipine on brain surface microvessels in rats. Neurol. Med.-Chir. (Tokyo) 34 (1994) 663
20. Kribben A., Witzke O., Hillen U., Barkhausen J., Daul A.E., and Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J. Am. Coll. Cardiol. 53 (2009) 1621
21. Lafreniere R., and Rosenberg S.A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 45 (1985) 3735
22. Lotze M.T., Grimm E.A., Mazumder A., Strausser J.L., and Rosenberg S.A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 41 (1981) 4420
23. Mann H., Ward J.H., and Samlowski W.E. Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology 176 (1990) 191
24. Martin S., Maruta K., Burkart V., Gillis S., and Kolb H. IL-1 and IFN-gamma increase vascular permeability. Immunology 64 (1988) 301
25. Maruo N., Morita I., Shirao M., and Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology 131 (1992) 710
26. Mertelsmann R., and Welte K. Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology 172 (1986) 400
27. Mier J.W., Vachino G., van der Meer J.W., Numerof R.P., Adams S., Cannon J.G., Bernheim H.A., Atkins M.B., Parkinson D.R., and Dinarello C.A. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. 8 (1988) 426
28. Mross K., Drevs J., Muller M., Medinger M., Marme D., Hennig J., Morgan B., Lebwohl D., Masson E., Ho Y.Y., Gunther C., Laurent D., and Unger C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 41 (2005) 1291
29. Mule J.J., Shu S., and Rosenberg S.A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J. Immunol. 135 (1985) 646
30. Nakarai T., Robertson M.J., Streuli M., Wu Z., Ciardelli T.L., Smith K.A., and Ritz J. Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J. Exp. Med. 180 (1994) 241
31. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., and Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161 (2003) 653
32. Nooteboom A., Van Der Linden C.J., and Hendriks T. Tumor necrosis factor-alpha and interleukin-1beta mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood. Crit. Care Med. 30 (2002) 2063
33. O'Brien Jr. J.M., Ali N.A., Aberegg S.K., and Abraham E. Sepsis. Am. J. Med. 120 (2007) 1012
34. Ognibene F.P., Rosenberg S.A., Lotze M., Skibber J., Parker M.M., Shelhamer J.H., and Parrillo J.E. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94 (1988) 750
35. Panelli M.C., White R., Foster M., Martin B., Wang E., Smith K., and Marincola F.M. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2 (2004) 17
36. Papa M.Z., Mule J.J., and Rosenberg S.A. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res. 46 (1986) 4973
37. Papa M.Z., Vetto J.T., Ettinghausen S.E., Mule J.J., and Rosenberg S.A. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 46 (1986) 5618
38. Perazella M.A. Current status of gadolinium toxicity in patients with kidney disease. Clin. J. Am. Soc. Nephrol. 4 (2009) 461
39. Pietsch H., Lengsfeld P., Steger-Hartmann T., Lowe A., Frenzel T., Hutter J., and Sieber M.A. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest. Radiol. 44 (2009) 226
40. Rayner A.A., Grimm E.A., Lotze M.T., Wilson D.J., and Rosenberg S.A. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J. Natl. Cancer Inst. 75 (1985) 67
41. Rosen M.A., and Schnall M.D. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin. Cancer Res. 13 (2007) 770s
42. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 (1994) 907
43. Samlowski W.E. Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity. In: Salvemini D., Billiar T.R., and Vodovotz Y. (Eds). Nitric Oxide and Inflammation (2001), Birkhäuser Verlag, Basel 249
44. Samlowski W.E., Petersen R., Cuzzocrea S., Macarthur H., Burton D., McGregor J.R., and Salvemini D. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat. Med. 9 (2003) 750
45. Samlowski W.E., Wong B., and Vogelzang N.J. Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. BJU Int. 102 (2008) 162
46. Sana T.R., Wu Z., Smith K.A., and Ciardelli T.L. Expression and ligand binding characterization of the beta-subunit (p75) ectodomain of the interleukin-2 receptor. Biochemistry 33 (1994) 5838
47. Saris S.C., Patronas N.J., Rosenberg S.A., Alexander J.T., Frank J., Schwartzentruber D.J., Rubin J.T., Barba D., and Oldfield E.H. The effect of intravenous interleukin-2 on brain water content. J. Neurosurg. 71 (1989) 169
48. Schaafsma M.R., Falkenburg J.H., Landegent J.E., Duinkerken N., Osanto S., Ralph P., Kaushansky K., Wagemaker G., Van Damme J., Willemze R., et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood 78 (1991) 1981
49. Shames D.M., Kuwatsuru R., Vexler V., Muhler A., and Brasch R.C. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn. Reson. Med. 29 (1993) 616
50. Torfgard K.E., and Ahlner J. Mechanisms of action of nitrates. Cardiovasc. Drugs Ther. 8 (1994) 701
51. Vallance P., Collier J., and Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2 (1989) 997
52. Watts R.G., Wright J.L., Atkinson L.L., and Merchant R.E. Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurgery 25 (1989) 202
53. Weiss A. T lymphocyte activation. In: Paul W. (Ed). Fundamental Immunology (1993), Raven Press, New York 467
54. Yim C.Y., McGregor J.R., Kwon O.D., Bastian N.R., Rees M., Mori M., Hibbs Jr. J.B., and Samlowski W.E. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J. Immunol. 155 (1995) 4382